Search results for "Nanoparticles"

showing 10 items of 1286 documents

Lipid Nanoparticles for Drug Targeting to the Brain

2012

In this chapter, the main production methods of lipid nanostructures such as solid lipid nanoparticles and nanostructured lipid carriers, and their application are described. In particular, we describe the strategies commonly used to obtain lipid nanoparticles to overcome the blood-brain barrier (BBB) for the treatment of several brain diseases. The use of these carriers as targeted drug delivery systems is associated with many advantages that include excellent storage stability, easy production without the use of any organic solvent, the possibility of steam sterilization and lyophilization, and large scale production. They exhibit good stability during long-term storage, consist of physio…

DrugChemistrymedia_common.quotation_subjectOrganic solventNanoparticleNanotechnologySteam sterilizationTargeted drug deliverySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNanoparticles for drug delivery to the brainGenerally recognized as safeSolid lipid nanoparticlesolid lipid nanoparticles blood brain barriermedia_common
researchProduct

Immunotoxicity of Therapeutic Antibodies and Nanoparticles.

2020

Therapeutic antibodies and nanotherapeutic drugs are of great concern due to their widespread use against numerous diseases worldwide. They are frequently used for targeted therapy under the assumption that they cause fewer side effects than nontargeted drugs. Despite their specificity and particular design for therapeutic actions, they might still exhibit unintended adverse effects in the immune system. Immunotoxicity reactions are mediated by immunomodulation, including immunostimulation and immunosuppression. The present review gives an overview on the adverse immunotoxic effects induced by therapeutic antibodies as well as nanotherapeutic drugs. In this context, future methods combining…

DrugCytotoxicity ImmunologicDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectImmunologyContext (language use)BioengineeringMonoclonal antibodyAntibodiesTargeted therapyImmunomodulationImmune systemImmunology and AllergyMedicineAnimalsHumansAdverse effectmedia_commonbusiness.industryImmunosuppressionTolerabilityDrug DesignImmune SystemImmunologyNanoparticlesbusinessCritical reviews in immunology
researchProduct

Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy.

2021

Gene-directed enzyme prodrug therapy (GDEPT) has been intensively studied as a promising new strategy of prodrug delivery, with its main advantages being represented by an enhanced efficacy and a reduced off-target toxicity of the active drug. In recent years, numerous therapeutic systems based on GDEPT strategy have entered clinical trials. In order to deliver the desired gene at a specific site of action, this therapeutic approach uses vectors divided in two major categories, viral vectors and non-viral vectors, with the latter being represented by chemical delivery agents. There is considerable interest in the development of non-viral vectors due to their decreased immunogenicity, higher…

DrugDendrimersmedicine.medical_treatmentmedia_common.quotation_subjectGenetic VectorsPharmaceutical ScienceEnzyme TherapyComputational biologyReviewdendrimerdelivery vehiclesAnalytical ChemistryTargeted therapyViral vectornon-viral vectorQD241-441DendrimerGDEPTDrug DiscoverymedicineAnimalsHumansProdrugsPhysical and Theoretical ChemistryGenemedia_commonchemistry.chemical_classificationGDEP therapyImmunogenicityOrganic ChemistrytransgeneGene Transfer TechniquesGenetic TherapyProdrugtargeted therapyEnzymesEnzymechemistrygene delivery systemChemistry (miscellaneous)Molecular MedicineNanoparticlesMolecules (Basel, Switzerland)
researchProduct

The zebrafish embryo as an in vivo model for screening nanoparticle-formulated lipophilic anti-tuberculosis compounds.

2021

ABSTRACT With the increasing emergence of drug-resistant Mycobacterium tuberculosis strains, new and effective antibiotics against tuberculosis (TB) are urgently needed. However, the high frequency of poorly water-soluble compounds among hits in high-throughput drug screening campaigns is a major obstacle in drug discovery. Moreover, in vivo testing using conventional animal TB models, such as mice, is time consuming and costly, and represents a major bottleneck in lead compound discovery and development. Here, we report the use of the zebrafish embryo TB model for evaluating the in vivo toxicity and efficacy of five poorly water-soluble nitronaphthofuran derivatives, which were recently id…

DrugIn vivo efficacyTuberculosismedicine.drug_classmedia_common.quotation_subjectAntibioticsAntitubercular AgentsNeuroscience (miscellaneous)Medicine (miscellaneous)Anti-tuberculosis drugsPharmacologyBiologyGeneral Biochemistry Genetics and Molecular BiologyMycobacterium tuberculosisMiceImmunology and Microbiology (miscellaneous)In vivoZebrafish as a Disease ModelmedicineAnimalsTuberculosisZebrafishmedia_commonIn vivo toxicityDrug discoveryMycobacterium tuberculosismedicine.diseasebiology.organism_classificationIn vitroZebrafish tuberculosis modelDrug developmentNanoparticlesResearch Article
researchProduct

PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen.

2018

The oral controlled release (CR) formulations have become more important in recent years. Among them, the polymeric nanoparticles have been thoroughly studied during the last decades, consequently they are extensively employed for a broad range of applications and drugs. The objective of this research was to develop polymeric nanoparticles (NPs) of ibuprofen with poly(lactic-co-glycolic) acid (PLGA) as polymer, and to test their applicability for oral CR formulations development. Different proportions of drug/polymer were employed to develop the ibuprofen NPs and their in vitro release profiles were analysed. The in situ segmental permeability of ibuprofen was tested in Wistar rat and demon…

DrugMaleColonPolymersmedia_common.quotation_subjectPharmaceutical ScienceIbuprofen02 engineering and technologyAbsorption (skin)030226 pharmacology & pharmacyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIn vivomedicineAnimalsLactic AcidRats Wistarmedia_commonchemistry.chemical_classificationDrug CarriersChromatographyorganic chemicalstechnology industry and agriculturePolymer021001 nanoscience & nanotechnologyIbuprofenControlled releaseRatsPLGAchemistryIntestinal AbsorptionPermeability (electromagnetism)Delayed-Action PreparationsNanoparticles0210 nano-technologyPolyglycolic Acidmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

2007

An increasing number of newly developed drugs show bioavailability problems due to poor water solubility. Formulating the drugs as nanosuspensions may help to overcome these problems by increasing saturation solubility and dissolution velocity. In the present study the bioavailability of the poorly soluble fenofibrate following oral administration was investigated in rats. Four formulations were tested: a nanosuspension type DissoCube(R), one solid lipid nanoparticle (SLN) preparation and two suspensions of micronized fenofibrate as reference formulations, one suspension in sirupus simplex and a second in a solution of hydroxyethy-cellulose in physiological saline. Both colloidal drug deliv…

DrugMalemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalDosage formPharmacokineticsFenofibrateSuspensionsSolid lipid nanoparticlemedicineAnimalsComputer SimulationTissue DistributionSolubilityRats Wistarmedia_commonHypolipidemic AgentsFenofibrateChemistryLipidsBioavailabilityRatsSolubilityDrug deliveryNanoparticlesmedicine.drugAdvanced drug delivery reviews
researchProduct

Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies

2009

The prospect of improved cancer therapy using Solid Lipid Nanoparticles (SLNs) as drug delivery system is promising. Sev- eral obstacles frequently encountered with anticancer compounds, such as poor drug solubility, are overcome by delivering them using SLN. Moreover, the intravenous administration of drugs into SLNs can potentially enhance drug blood circulation time and improve drug per- formance by inducing accumulation into tumours by enhanced permeability and retention (EPR) effect. This paper deals with the devel- opment of SLN containing nimesulide, a non-steroidal anti-inflammatory drug with antitumour effect and low solubility in water. Here, SLNs carrying nimesulide were prepared…

DrugMaterials sciencemedia_common.quotation_subjectsolid lipid nanoparticles nimesulide drug deliveryBiomedical EngineeringPharmaceutical ScienceMedicine (miscellaneous)BioengineeringPharmacologyIn vitroSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSolid lipid nanoparticleDrug deliveryZeta potentialmedicineSolubilityCytotoxicityBiotechnologymedia_commonNimesulidemedicine.drugCurrent Nanoscience
researchProduct

Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity.

2005

Solid lipid nanoparticles (SLNs) containing tamoxifen, a nons- teroidal antiestrogen used in breast cancer therapy, were prepared by microemulsion and precipitation techniques. Tamoxifen loaded SLNs seem to have dimensional properties useful for parenteral administration, and in vitro plasmatic drug release studies demon- strated that these systems are able to give a prolonged release of the drug in the intact form. Preliminary study of antiproliferative ac- tivity in vitro, carried out on MCF-7 cell line (human breast cancer cells), demonstrated that SLNs, containing tamoxifen showed an antitumoral activity comparable to free drug. The results of char- acterization studies and of in vitro …

DrugOctanolsMaterials scienceTime FactorsAntineoplastic Agents Hormonalmedia_common.quotation_subjectPharmaceutical SciencePharmacologyColloidal Drug Delivery Systems Solid Lipid Nanoparticles (SLNs) TamoxifenBreast cancerDrug StabilityCell Line TumorSolid lipid nanoparticlemedicineHumansParticle Sizeskin and connective tissue diseasesmedia_commonCell ProliferationDrug CarriersWaterGeneral MedicineHydrogen-Ion Concentrationmedicine.diseaseAntiestrogenLipidsIn vitroNanostructuresbody regionsTamoxifenSolubilityDelayed-Action PreparationsCancer cellDrug carrierTamoxifenmedicine.drugDrug delivery
researchProduct

Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug.

2018

Abstract Atenolol is a drug widely used for the treatment of hypertension. However, the great drawback it presents is a low bioavailability after oral administration. To obtain formulations that allow to improve the bioavailability of this drug is a challenge for the pharmaceutical technology. The objective of this work was to increase the rate and extent of intestinal absorption of atenolol as model of a low permeability drug, developing a double technology strategy. To increase atenolol permeability an ion pair with brilliant blue was designed and the sustained release achieved through encapsulation in polymeric nanoparticles (NPs). The in vitro release studies showed a pH-dependent relea…

Drugmedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological Availability02 engineering and technology030226 pharmacology & pharmacyIntestinal absorptionPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIn vivoOral administrationmedicineAnimalsRats WistarAntihypertensive Agentsmedia_commonChromatographyChemistryBenzenesulfonates021001 nanoscience & nanotechnologyAtenololControlled releaseBioavailabilityPLGADrug LiberationAtenololIntestinal AbsorptionNanoparticles0210 nano-technologymedicine.drugInternational journal of pharmaceutics
researchProduct

Nanocarriers for respiratory diseases treatment: Recent advances and current challenges

2014

Pulmonary delivery of locally-acting drugs encapsulated in nanocarriers provides several advantages for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary diseases, cystic fibrosis, tuberculosis and lung cancer. These advantages include, among others, sustained drug delivery to the lungs, reduced therapeutic dose and improved patient compliance. The aim of this review is to give an updated overview on recent advances recorded in the last few years in this field as well as on the major challenges still existing and that remain to be overcome before any clinical application. After an outline on the cellular and extracellular barriers affecting drug delivery to…

Drugmedicine.medical_specialtymedia_common.quotation_subjectpulmonary deliveryAntitubercular AgentsMicrobial Sensitivity TestsGene deliveryPharmacologyCystic fibrosisTherapeutic indexDrug DiscoverymedicineAnimalsHumansTuberculosisIntensive care medicinemedia_commonDrug CarriersLungrespiratory diseasesbusiness.industryMycobacterium tuberculosisGeneral Medicinemedicine.diseaseinhalation of polymeric- and lipid-based nanocarriermedicine.anatomical_structurelung targetingTargeted drug deliveryDrug deliverymucus penetrationNanoparticlesNanocarriersbusinessDefense mechanism
researchProduct